Showing 501 - 520 results of 18,229 for search 'significantly ((((((linear decrease) OR (a decrease))) OR (nn decrease))) OR (greater decrease))', query time: 0.53s Refine Results
  1. 501
  2. 502
  3. 503
  4. 504
  5. 505
  6. 506
  7. 507
  8. 508

    Univariate analyses. by Zachary E. M. Giovannini-Green (22008277)

    Published 2025
    “…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. This study identified the demographics of Canadians who require extra support during a health crisis. …”
  9. 509

    Overview of individuals in the study. by Zachary E. M. Giovannini-Green (22008277)

    Published 2025
    “…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. This study identified the demographics of Canadians who require extra support during a health crisis. …”
  10. 510

    Multivariate analyses. by Zachary E. M. Giovannini-Green (22008277)

    Published 2025
    “…ED utilization by individuals with psychotic disorders increased during the first year of the COVID-19 pandemic, while ED use by most Canadians decreased. This study identified the demographics of Canadians who require extra support during a health crisis. …”
  11. 511
  12. 512
  13. 513

    <i>rfbV</i> gene triplication in S. Paratyphi A increases VL O-ag production and reduces C3b deposition. by Fermin E. Guerra (6084545)

    Published 2025
    “…(E) Extracted LPS subjected to gel electrophoresis followed by silver staining showing decreased VL O-ag production in <i>S.</i> Paratyphi A with a single <i>rfbV</i> gene copy compared to wild-type <i>S.…”
  14. 514
  15. 515
  16. 516
  17. 517
  18. 518

    DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

    Published 2025
    “…The trends in the utilization and expenditure of anticoagulants were examined using linear regression analysis.</p><p>Results</p><p>From 2019 to 2023, the DDDs of rivaroxaban demonstrated a significant annual increase in most hospitals (<i>p</i> < 0.05). …”
  19. 519
  20. 520